iSpecimen (ISPC)
NASDAQ:ISPC
Want to see ISPC full AI Analyst Report?
ISPC Stock Chart & Stats
$0.31
-$0.03(-1.03%)
At close: 4:00 PM EST
$0.31
-$0.03(-1.03%)
Day’s Range― - ―
52-Week Range$2.39 - $127.20
Previous CloseN/A
Volume25.67K
Average Volume (3M)8.88M
Market Cap
$3.84M
Enterprise Value-$2.21M
Total Cash (Recent Filing)$2.82M
Total Debt (Recent Filing)$254.99K
Price to Earnings (P/E)―
Beta1.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,437,157
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.62
P/FCF Ratio-0.28
Enterprise Value/Market Cap-0.58
Enterprise Value/Revenue-2.15
Enterprise Value/Gross Profit7.26
Enterprise Value/Ebitda0.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Marketplace Business ModeliSpecimen’s technology-enabled marketplace connects diverse buyers (pharma, biotech, diagnostics, academia) with a broad supplier base, creating durable network effects and recurring service-fee revenue. A multichannel buyer/supplier mix and platform-led procurement increase stickiness and long-term revenue potential versus one-off services.
Low Financial LeverageLow debt relative to equity gives iSpecimen structural financial flexibility during continued operating losses. Manageable leverage reduces near-term interest burden and bankruptcy risk, allowing the company to prioritize operational fixes and capital raises without an immediate heavy debt-service constraint, supporting resilience over months.
Streamlined Global Shipping & Supply ExpansionOperationally reducing transit times and costs is a structural improvement: faster, cheaper, and more reliable specimen fulfillment strengthens customer value proposition, supports higher fulfillment volumes, and expands access to rare specimens via European partners—advantages that improve competitive positioning and retention long term.
Bears Say
Sharp Revenue Decline & Severe LossesA near-50% TTM revenue drop combined with extremely negative margins signals structural demand or execution issues. Such severe operating losses erode scalability and make profitable unit economics elusive; absent sustained top-line stabilization, long-term viability and ability to invest in growth remain at risk over the coming months.
Persistent Cash Burn And Negative Free Cash FlowConsistent negative operating and free cash flow creates ongoing funding needs and elevates dilution risk. Reliance on external capital constrains strategic flexibility, limits sustained marketing or product investment, and forces management to prioritize short-term liquidity, which can hamper structural improvements and customer acquisition over months.
Nasdaq Noncompliance & Weakened EquityFailure to meet Nasdaq equity thresholds introduces listing risk that can materially affect access to public capital and investor confidence. Management must remedy equity shortfall within defined windows; inability to do so could lead to delisting, reduced liquidity, and higher future financing costs, compounding existing funding and operational pressures.
iSpecimen News
ISPC FAQ
What was iSpecimen’s price range in the past 12 months?
iSpecimen lowest stock price was $2.39 and its highest was $127.20 in the past 12 months.
What is iSpecimen’s market cap?
iSpecimen’s market cap is $3.84M.
When is iSpecimen’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were iSpecimen’s earnings last quarter?
Currently, no data Available
Is iSpecimen overvalued?
According to Wall Street analysts iSpecimen’s price is currently Overvalued.
Does iSpecimen pay dividends?
iSpecimen does not currently pay dividends.
What is iSpecimen’s EPS estimate?
iSpecimen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iSpecimen have?
iSpecimen has 1,437,157 shares outstanding.
What happened to iSpecimen’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of iSpecimen?
Currently, no hedge funds are holding shares in ISPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
iSpecimen
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Technical Analysis
―
Intelligent Bio Solutions
―
BioNexus Gene Lab Corp
―
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
4.42% Mutual Funds
― Other Institutional Investors
95.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---